Table 1

Patients features

DrugPatientsMean exposure to drug (years)Mean age (years)Disease (n)
Adalimumab914.957.47AS: 28
PsA: 42
RA: 15
Takayasu: 1
Sarcoidosis: 5
Etanercept945.361.3AS: 22
PsA: 27
RA: 45
Infliximab904.557.97AS: 47
PsA: 26
EA: 2
RA: 5
BD: 5
Takayasu: 1
SAPHO: 1
Sarcoidosis: 3
Certolizumab411.552.41AS: 6
PsA: 25
RA: 10
Golimumab443.154.68AS: 8
PsA: 31
RA: 4
EA: 1
Rituximab2252.961.96RA: 158
SSc: 54
AAV: 8
IIM: 5
SLE: 6
SS: 3
Sweet: 1
Tocilizumab383.562.9RA: 27
GCA: 11
Sarilumab121.161.25RA: 12
Ustekinumab72.159.71PsA: 7
Secukinumab752.155.16AS: 20
PsA: 55
Ixekizumab60.557.16PsA: 6
Canakinumab11.050.0Still: 1
Abatacept552.762.2RA: 55
Baricitinib681.960.46RA: 68
Tofacitinib121.261.18RA: 12
  • AAV, ANCA-associated vasculitis; AS, ankylosing spondylitis; BD, Behçet disease; EA, enteropathic arthritis; GCA, giant cell arteritis; IIM, idiopathic inflammatory myopathies; PsA, psoriathic arthritis; RA, rheumatoid arthritis; SAPHO, synovitis, acne, pustulosis, hyperostosis, osteitis; SLE, systemic lupus erythematous; SS, Sjogren’s syndrome; SSc, systemic sclerosis.